Sionna Therapeutics Inc
NASDAQ:SION
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sionna Therapeutics Inc
NASDAQ:SION
|
US |
|
Evoke Pharma Inc
NASDAQ:EVOK
|
US |
|
Xvivo Perfusion AB
STO:XVIVO
|
SE |
|
N
|
Nanjing Baose Co Ltd
SZSE:300402
|
CN |
|
M
|
Makamer Holdings Inc
OTC:HWIN
|
US |
|
R
|
RMS Mezzanine as
XBER:PVT
|
CZ |
|
Shinsegae Inc
KRX:004170
|
KR |
|
F
|
Farmae SpA
MIL:FAR
|
IT |
|
S
|
Sharkninja Inc
NYSE:SN
|
US |
|
Heartland Express Inc
NASDAQ:HTLD
|
US |
Sionna Therapeutics Inc
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2025-02-07. The firm is focused on researching and developing novel medicines for cystic fibrosis. The company is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). The company is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. The company is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2025-02-07. The firm is focused on researching and developing novel medicines for cystic fibrosis. The company is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). The company is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. The company is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
